Divis Laboratories Ltd. | DIVISLAB | NSE - Pharmaceuticals
INR in Million. Fiscal year ends in March. Figures are consolidated and restated..
Upgrade Membership to see 10 year accurate financial statements.
Chart | 2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|---|
Cash and cash equiva... |
![]() | 787 | 1,125 | 1,153 | 1,226 | 21,560 |
Short-term investment |
![]() | 16,307 | 18,893 | 13,983 | 9,714 | 0 |
Accounts receivables |
![]() | 8,984 | 10,144 | 11,634 | 14,134 | 16,765 |
Inventories |
![]() | 13,199 | 13,507 | 17,723 | 18,639 | 21,452 |
Deferred income taxes |
![]() | 0 | 0 | 0 | 791 | 343 |
Other current assets |
![]() | 827 | 1,684 | 2,007 | 2,296 | 1,627 |
Total current assets |
![]() | 40,105 | 45,351 | 46,501 | 46,798 | 61,747 |
Gross property plant... |
![]() | 15,559 | 19,896 | 20,837 | 27,732 | 36,947 |
Accumulated Depriciat... |
![]() | 0 | 0 | 0 | 0 | 0 |
Net property, plant and Eq... |
![]() | 15,559 | 19,896 | 20,837 | 27,732 | 36,947 |
Work in Progress |
![]() | 4,436 | 1,198 | 4,919 | 9,197 | 7,106 |
Miscellaneous Investment |
![]() | 0.12 | 390 | 5,813 | 353 | 553 |
Deferred income taxes |
![]() | 36 | 10 | 216 | 44 | 718 |
Intangible assets |
![]() | 33 | 66 | 41 | 36 | 50 |
Goodwill |
![]() | 0 | 0 | 0 | 0 | 0 |
Other long-term assets |
![]() | 1,417 | 920 | 2,056 | 1,197 | 620 |
Total non-current assets |
![]() | 21,480 | 22,480 | 33,882 | 38,559 | 45,994 |
Total assets |
![]() | 61,585 | 67,832 | 80,383 | 85,357 | 107,741 |
Short-term debt |
![]() | 357 | 631 | 1,056 | 336 | 4 |
Accounts Payable... |
![]() | 3,839 | 4,112 | 4,923 | 5,907 | 7,632 |
Provisions |
![]() | 13 | 9 | 11 | 25 | 25 |
Taxes Payable |
![]() | 0 | 0 | 42 | 99 | 60 |
Deferred Revenues |
![]() | 0 | 0 | 0 | 0 | 0 |
Capital Leases |
![]() | 0 | 0 | 0 | 8 | 8 |
Other current liabilities |
![]() | 2,386 | 1,755 | 2,436 | 2,893 | 3,396 |
Total current liabilities |
![]() | 6,594 | 6,507 | 8,468 | 9,268 | 11,125 |
Long-term debt |
![]() | 0 | 0 | 0 | 0 | 0 |
Investments Liabilities |
![]() | 0 | 0 | 0 | 0 | 0 |
Deferred tax liabilities |
![]() | 1,264 | 1,927 | 2,212 | 2,740 | 3,381 |
Provisions |
![]() | 153 | 150 | 132 | 205 | 253 |
Capital Leases |
![]() | 0 | 0 | 0 | 45 | 37 |
Other longterm liabilities |
![]() | 0 | 0 | 0 | 0 | 0 |
Total non-current liabilities |
![]() | 1,417 | 2,076 | 2,344 | 2,990 | 3,670 |
Total liabilities |
![]() | 8,011 | 8,584 | 10,811 | 12,258 | 14,795 |
Share Capital |
![]() | 531 | 531 | 531 | 531 | 531 |
Share premium |
![]() | 0 | 0 | 0 | 0 | 0 |
Retained earnings |
![]() | 53,043 | 58,625 | 69,041 | 72,568 | 92,415 |
Accumulated other equity |
![]() | 0 | 92 | 0 | 0 | 0 |
Preferred Stock |
![]() | 0 | 0 | 0 | 0 | 0 |
Minority Interest |
![]() | 0 | 0 | 0 | 0 | 0 |
Total Equity |
![]() | 53,574 | 59,248 | 69,572 | 73,099 | 92,946 |
Total Liabilities and Equity |
![]() | 61,585 | 67,832 | 80,383 | 85,357 | 107,741 |
Cash per Share |
![]() | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade |
Cash, Current Inv Per share |
![]() | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade |